www. Clinical trial results.org In-stent Restenosis SIRIUS: 8 Month Angiographic Follow-up SIRIUS: 8 Month Angiographic Follow-up Restenosis RatesRestenosis Rates In-segment Restenosis Sirolimus Stent Bare Stent 91% reduction p0.001 Sirolimus Stent Bare Stent 75% reduction p0.001 www. Clinical trial results.org Late Lumen Loss (mm) Sirolimus Stent Proximal Margin p0.001 SIRIUS: 8 Month Angiographic Follow-up SIRIUS: 8 Month Angiographic Follow-up Late Lumen LossLate Lumen Loss Bare Stent In-stent p0.001 Distal Margin p0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent www. Clinical trial results.org Number of In-segment Restenosis Events Prevented per 100 Patients All patients SIRIUS: Restenosis Events PreventedSIRIUS: Restenosis Events Prevented DiabetesLAD Small Vessels Long Lesions www. Clinical trial results.org MACE SIRIUS: Clinical Events Through 9 MonthsSIRIUS: Clinical Events Through 9 Months Target Vessel Failure* Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent *Primary clinical endpoint; defined as cardiac death, MI, TVR p0.001 p0.001